Catalyst Pharmaceuticals Inc (CPRX)
ROE
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 71 410 | 62 037 | 115 549 | 99 406 | 83 079 | 66 917 | 54 498 | 45 060 |
| Kapitał własny | w tys. USD | 387 881 | 348 548 | 375 294 | 333 661 | 300 421 | 270 041 | 241 092 | 220 221 |
| ROE | 18,41% | 17,80% | 30,79% | 29,79% | 27,65% | 24,78% | 22,60% | 20,46% |
2023/Q4 obliczenia
ROE = Zysk netto (ttm) ÷ Kapitał własny
= $71 410K ÷ $387 881K
= 18,41%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROE
Catalyst Pharmaceuticals Inc
CPRX
18,41%
Amphastar Pharmaceuticals Inc
AMPH
21,51%
Arcus Biosciences Inc
RCUS
-66,45%
Dynavax Technologies Corp.
DVAX
-1,03%
Harmony Biosciences Holdings Inc
HRMY
27,59%
Ironwood Pharmaceuticals Inc
IRWD
—
Ligand Pharmaceuticals, Inc.
LGND
7,44%
Myriad Genetics, Inc.
MYGN
-33,62%
Pacira BioSciences Inc
PCRX
4,82%
Supernus Pharmaceuticals Inc
SUPN
0,14%
Xencor Inc
XNCR
-18,85%